PSMA (prostate specific membrane antigen) is a type II integral membrane glycoprotein (1,2). It is highly expressed in the prostate epithelium, and also expressed in the small intestine, brain, kidney, liver, spleen, colon and the capillary endothelium of a variety of tumors. PSMA is expressed specifically in jejunum brush border membranes. In the brain, PSMA is highly expressed in the ventral striatum and brain stem. PSMA cytosolic isoform is the most abundant form in normal prostate tissue, while the membrane-bound PSMA-1 form is found in primary prostate tumors. Recent evidence has shown that PSMA is also expressed in tumor-associated neovasculature and may become an effective target for monoclonal antibody-based anti-neovasculature therapy (3).

Suitable for use in FLISA and Western Blot. Other applications not tested.

FLISA: 0.1-1ug/ml Western Blot: 1-3ug/ml Optimal dilutions to be determined by the researcher.

Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Note: Applications are based on unconjugated antibody.

Synthetic peptide derived from the C-terminal region of the human PSMA.

Supplied as a liquid in PBS, pH 7.2. No preservatives added. Labeled with MaxLight™650.

Purified by Protein A affinity chromatography.

Recognizes human PSMA protein at ~90kD. Reactivity has been confirmed with human prostate cancer LNCap cell lysates.